BioAlliance Pharma SA (Paris: BIO) today announces, following the end of the European Mutual Recognition Procedure last December (with France as Reference Member State) that it has just received the Marketing Authorisation for Loramyc(R) in the UK and Denmark.
The grant of the Marketing Authorisation in the UK represents an important milestone for BioAlliance Pharma especially with the payment of EUR 2.5 million by its partner SpePharm, according to the terms of the agreement signed in March 2007, which led to the creation of the SpeBio JV for the distribution of Loramyc(R) in Europe.
"We are delighted of this European success which confirms the quality and the efficiency of our development and regulatory teams and experts. Currently being launched in France, Loramyc(R) will be present on the European market in 2008 as planned. The other main European countries should grant their Marketing Authorisation for Loramyc(R) in the very near future", stated Dominique Costantini Chief Executive Officer.
No comments:
Post a Comment